Shopping Cart
Remove All
Your shopping cart is currently empty
SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3, 420 times for Tyk2).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $73 | In Stock | In Stock | |
| 5 mg | $193 | In Stock | In Stock | |
| 10 mg | $313 | In Stock | In Stock | |
| 25 mg | $538 | In Stock | In Stock | |
| 50 mg | $859 | In Stock | In Stock | |
| 100 mg | $1,380 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $176 | In Stock | In Stock |
| Description | SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3, 420 times for Tyk2). |
| In vitro | SHR0302 (1nM-10μM) exerted an inhibitory effect on the activation, proliferation and migration of hepatic stellate cells (HSCs). SHR0302 induced the apoptosis of HSCs. The pharmacological inhibition of the JAK1/signal transducer and activator of transcription (STAT)3 pathway led to the disruption of functions essential for HSC[1]. |
| In vivo | SHR0302 may attenuate the severity of AA rats, partially through reducing Th17 function and total B cell proportion by inhibiting JAK1-STAT3 phosphorylation[2]. |
| Synonyms | ARQ252 |
| Molecular Weight | 414.48 |
| Formula | C18H22N8O2S |
| Cas No. | 1445987-21-2 |
| Smiles | [H][C@@]12C[C@H](C[C@]1([H])CN(C2)C(=O)Nc1nc(OC)ns1)N(C)c1ncnc2[nH]ccc12 |
| Relative Density. | 1.507 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 30 mg/mL (72.38 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (4.83 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.